One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

In a groundbreaking clinical trial, immunotherapy alone eliminated rectal cancer in all 14 participants. This study, the ...

The following is a summary of “Efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination therapy versus platinum-based chemotherapy as a first-line treatment of advanced urothelial cancer ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy. Now, the company has made a move to try to make sure it isn ...

Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous cell carcinoma of the anal canal (SCAC) was knocked back by the FDA, but new data could get the programme back ...

Technologies announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU ...

Patients with a nonrejection-related diagnosis according to the 2019 Banff classification who were reclassified as MVI, ...

In this case series, of the reported 46 case-patients, 45 cases were due to exposures to infected poultry or dairy cows and were mild in severity, with no evidence of human-to-human transmission. 2.